Penumbra, Inc. (NYSE:PEN) Stock Holdings Lifted by Artisan Partners Limited Partnership

Artisan Partners Limited Partnership lifted its position in Penumbra, Inc. (NYSE:PEN) by 1.9% in the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 296,058 shares of the company’s stock after acquiring an additional 5,470 shares during the quarter. Artisan Partners Limited Partnership owned approximately 0.77% of Penumbra worth $70,308,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in PEN. True Wealth Design LLC purchased a new stake in shares of Penumbra in the third quarter valued at $26,000. UMB Bank n.a. lifted its stake in Penumbra by 57.4% in the 4th quarter. UMB Bank n.a. now owns 192 shares of the company’s stock worth $46,000 after acquiring an additional 70 shares in the last quarter. Mather Group LLC. boosted its position in Penumbra by 208.0% during the 4th quarter. Mather Group LLC. now owns 308 shares of the company’s stock worth $73,000 after acquiring an additional 208 shares during the period. Jones Financial Companies Lllp grew its stake in Penumbra by 25.0% during the 4th quarter. Jones Financial Companies Lllp now owns 375 shares of the company’s stock valued at $89,000 after acquiring an additional 75 shares in the last quarter. Finally, Advisors Asset Management Inc. increased its holdings in shares of Penumbra by 11.5% in the 3rd quarter. Advisors Asset Management Inc. now owns 416 shares of the company’s stock valued at $81,000 after purchasing an additional 43 shares during the period. Institutional investors and hedge funds own 88.88% of the company’s stock.

Insider Activity at Penumbra

In related news, Director Arani Bose sold 12,000 shares of the company’s stock in a transaction on Tuesday, March 25th. The stock was sold at an average price of $283.77, for a total value of $3,405,240.00. Following the completion of the transaction, the director now directly owns 314,819 shares in the company, valued at approximately $89,336,187.63. This represents a 3.67 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Harpreet Grewal sold 167 shares of Penumbra stock in a transaction on Friday, January 3rd. The stock was sold at an average price of $241.28, for a total transaction of $40,293.76. Following the sale, the director now owns 8,530 shares in the company, valued at $2,058,118.40. This represents a 1.92 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 93,518 shares of company stock worth $26,400,219. Company insiders own 5.00% of the company’s stock.

Penumbra Stock Down 2.3 %

Shares of PEN stock opened at $268.89 on Friday. Penumbra, Inc. has a 12 month low of $148.00 and a 12 month high of $310.00. The company has a quick ratio of 3.25, a current ratio of 6.01 and a debt-to-equity ratio of 0.02. The firm has a market cap of $10.36 billion, a PE ratio of 790.84, a price-to-earnings-growth ratio of 2.83 and a beta of 0.51. The stock has a 50 day moving average of $274.49 and a 200-day moving average of $242.13.

Penumbra (NYSE:PEN) last released its earnings results on Tuesday, February 18th. The company reported $0.97 EPS for the quarter, beating the consensus estimate of $0.88 by $0.09. The firm had revenue of $315.52 million during the quarter, compared to analysts’ expectations of $311.63 million. Penumbra had a net margin of 1.17% and a return on equity of 9.74%. On average, equities analysts predict that Penumbra, Inc. will post 3.67 EPS for the current year.

Analyst Upgrades and Downgrades

PEN has been the subject of several research reports. Truist Financial raised their price target on shares of Penumbra from $285.00 to $325.00 and gave the stock a “buy” rating in a report on Wednesday, February 19th. Oppenheimer began coverage on shares of Penumbra in a report on Tuesday, December 17th. They set an “outperform” rating and a $275.00 price target on the stock. Needham & Company LLC reiterated a “hold” rating on shares of Penumbra in a report on Wednesday, February 19th. Wells Fargo & Company boosted their target price on Penumbra from $275.00 to $305.00 and gave the company an “overweight” rating in a research note on Wednesday, February 19th. Finally, StockNews.com lowered Penumbra from a “buy” rating to a “hold” rating in a research report on Friday, February 28th. Four equities research analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $294.47.

Penumbra Company Profile

Penumbra, Inc, together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX.